Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 88

1.

Outcome and impact of post-remission strategy after MIDAM regimen in patients with relapsing or refractory acute myeloid leukemia.

Bahashwan S, Moluçon-Chabrot C, Hermet E, Ravinet A, Douge A, Veronese L, Tchirkov A, Lemal R, Berger MG, Veyrat-Masson R, Tournilhac O, Bay JO, Guièze R.

Am J Hematol. 2019 Jan;94(1):E32-E35. doi: 10.1002/ajh.25332. Epub 2018 Nov 25. No abstract available.

PMID:
30370957
2.

Administration of mylotarg 4 days after beginning of a chemotherapy including intermediate-dose aracytin and mitoxantrone (MIDAM regimen) produces a high rate of complete hematologic remission in patients with CD33+ primary resistant or relapsed acute myeloid leukemia.

Chevallier P, Roland V, Mahé B, Juge-Morineau N, Dubruille V, Guillaume T, Vigouroux S, Moreau P, Milpied N, Garand R, Avet-Loiseau H, Harousseau JL.

Leuk Res. 2005 Sep;29(9):1003-7. Epub 2005 Apr 8.

PMID:
16038726
3.

Long-term disease-free survival after gemtuzumab, intermediate-dose cytarabine, and mitoxantrone in patients with CD33(+) primary resistant or relapsed acute myeloid leukemia.

Chevallier P, Delaunay J, Turlure P, Pigneux A, Hunault M, Garand R, Guillaume T, Avet-Loiseau H, Dmytruk N, Girault S, Milpied N, Ifrah N, Mohty M, Harousseau JL.

J Clin Oncol. 2008 Nov 10;26(32):5192-7. doi: 10.1200/JCO.2007.15.9764. Epub 2008 Oct 14.

PMID:
18854573
4.

Advantage of MIDAM protocol in treatment of elderly patients with refractory and relapsing acute myeloid leukemia.

Filanovsky K, Shvidel L, Shtalrid M.

J Clin Oncol. 2010 Mar 1;28(7):e115-6; author reply e117-8. doi: 10.1200/JCO.2009.26.7930. Epub 2010 Jan 25. No abstract available.

PMID:
20100951
5.

Similarity of fractionated versus single dose(s) of gemtuzumab ozogamicin as part of the MIDAM salvage regimen in relapsed/refractory acute myeloid leukemia patients.

Peterlin P, Guillaume T, Delaunay J, Mohty M, Garnier A, Mahe B, Dubruille V, Blin N, Voldoire M, Touzeau C, Chauvin C, Gastinne T, Béné MC, Le Gouill S, Moreau P, Chevallier P.

Semin Hematol. 2016 Jul;53(3):216-7. doi: 10.1053/j.seminhematol.2016.06.001. Epub 2016 Jun 18. No abstract available.

PMID:
27496314
6.

[Clinical outcome of allogeneic hematopoietic stem cell transplantation with FLAG sequential busulfan/cyclophosphamide conditioning regimen for refractory/relapsed acute myeloid leukemia].

Liu W, Li Y, Qiu ZX, Yin Y, Sun YH, Xu WL, Wang Q, Liang ZY, Dong YJ, Wang LH, Cen QN, Wang MJ, Wang WS, Ou JP, Ren HY.

Zhonghua Nei Ke Za Zhi. 2018 Aug 1;57(8):576-581. doi: 10.3760/cma.j.issn.0578-1426.2018.08.008. Chinese.

PMID:
30060329
7.

[Effects of FLAG regimen in treatment of refractory or relapsed acute myeloid leukemia].

Wu XX, Da WM, Li HH, Zhao Y, Wang QS, Wang SH, Zhu HY.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2005 Jun;13(3):394-6. Chinese.

PMID:
15972128
8.
9.

High-dose ara-C and etoposide in refractory or relapsing acute leukemia.

Freund M, Link H, Diedrich H, LeBlanc S, Wilke HJ, Poliwoda H.

Cancer Chemother Pharmacol. 1991;28(6):487-90.

PMID:
1934254
10.

An operational definition of primary refractory acute myeloid leukemia allowing early identification of patients who may benefit from allogeneic stem cell transplantation.

Ferguson P, Hills RK, Grech A, Betteridge S, Kjeldsen L, Dennis M, Vyas P, Goldstone AH, Milligan D, Clark RE, Russell NH, Craddock C; UK NCRI AML Working Group.

Haematologica. 2016 Nov;101(11):1351-1358. Epub 2016 Aug 18.

11.

Sequential Intensified Conditioning Regimen Allogeneic Hematopoietic Stem Cell Transplantation in Adult Patients with Intermediate- or High-Risk Acute Myeloid Leukemia in Complete Remission: A Study from the Acute Leukemia Working Party of the European Group for Blood and Marrow Transplantation.

Malard F, Labopin M, Stuhler G, Bittenbring J, Ganser A, Tischer J, Michallet M, Kröger N, Schmid C, Huynh A, Hallek M, Savani BN, Mohty M, Nagler A.

Biol Blood Marrow Transplant. 2017 Feb;23(2):278-284. doi: 10.1016/j.bbmt.2016.11.002. Epub 2016 Nov 2.

12.

Impact of post-remission therapy in patients aged 65-70 years with de novo acute myeloid leukemia: a comparison of two concomitant randomized ALFA trials with overlapping age inclusion criteria.

Itzykson R, Gardin C, Pautas C, Thomas X, Turlure P, Raffoux E, Terré C, Fenaux P, Castaigne S, Dombret H, Boissel N; Acute Leukemia French Association (ALFA).

Haematologica. 2011 Jun;96(6):837-44. doi: 10.3324/haematol.2010.036921. Epub 2011 Apr 1.

14.

IDA-FLAG regimen for the therapy of primary refractory and relapse acute leukemia: a single-center experience.

Yavuz S, Paydas S, Disel U, Sahin B.

Am J Ther. 2006 Sep-Oct;13(5):389-93.

PMID:
16988532
15.

[Clinical Efficacy of Decitabine Combined with CAG Regimen for Myelodysplastic Syndrome-RAEB and Refractory Acute Myeloid Leukemia].

Yang XL, Wu YM, Cao YB, Li XH, Xu LX, Liu ZY, Liu B, Yan B, Li SW, DA WM, Wu XX.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Aug;23(4):1056-61. doi: 10.7534/j.issn.1009-2137.2015.04.030. Chinese.

PMID:
26314446
16.

[High doses of cytosine arabinoside in the treatment of patients with acute relapsing or refractory leukemia].

Lobato-Mendizábal E, Ruiz-Argüelles GJ, Marín-López A.

Rev Invest Clin. 1989 Apr-Jun;41(2):139-45. Review. Spanish.

PMID:
2675236
17.

Long-term outcome after a treosulfan-based conditioning regimen for patients with acute myeloid leukemia: A report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation.

Nagler A, Labopin M, Beelen D, Ciceri F, Volin L, Shimoni A, Foá R, Milpied N, Peccatori J, Polge E, Mailhol A, Mohty M, Savani BN.

Cancer. 2017 Jul 15;123(14):2671-2679. doi: 10.1002/cncr.30646. Epub 2017 Mar 22.

18.

[Clinical resarch of decitabine combined with modified CAG regimen for treatment of relapsed or refractory acute myeloid leukemia].

Zhu CY, Liu SY, Niu JH, Zhang Q, Yang H, Zhu HY, Yu L, Jing Y.

Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2015 Feb;23(1):88-93. doi: 10.7534/j.issn.1009-2137.2015.01.017. Chinese.

PMID:
25687052
19.

Mitoxantrone as a single agent and in combination chemotherapy in patients with refractory acute leukemia.

Paciucci PA, Cuttner J, Holland JF.

Semin Oncol. 1984 Sep;11(3 Suppl 1):36-40.

PMID:
6385264
20.

Daunorubicin, cytarabine and fludarabine (DAF) for remission induction in relapsed or refractory acute myeloid leukemia. Evaluation of safety, tolerance and early outcome--Polish Adult Leukemia Group (PALG) pilot study.

Hołowiecki J, Grosicki S, Kyrcz-Krzemien S, Skotnicki AB, Piatkowska-Jakubas B, Warzocha K, Seferynska I, Zdziarska B.

Ann Hematol. 2008 May;87(5):361-7. Epub 2007 Dec 12.

PMID:
18074133

Supplemental Content

Support Center